van der Sluis Wouter B, Buncamper Marlon E, Bouman Mark-Bram, Elfering Lian, Özer Müjde, Bogaarts Martijn, Steenbergen Renske D M, Heideman Daniëlle A M, Mullender Margriet G
From the *Department of Plastic, Reconstructive and Hand Surgery, †EMGO + Institute for Health and Care Research, ‡Center of Expertise on Gender Dysphoria, and §Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
Sex Transm Dis. 2016 Aug;43(8):503-5. doi: 10.1097/OLQ.0000000000000476.
Worldwide, transgender women are a high burden population for sexually transmitted diseases. Neovaginal high-risk human papillomavirus (hrHPV) infection has been documented among transgender women, but its prevalence remains unclear. The objective of this study was to determine the prevalence of neovaginal hrHPV in a sample of transgender women in The Netherlands.
Between June 2015 and December 2015, neovaginal samples were obtained from all transgender women who underwent vaginoplasty and attended our outpatient clinic for postoperative follow-up at least 1 year after surgery. High-risk HPV DNA detection and partial genotyping was performed by the HPV-risk assay. Genotyping of non-16/18-hrHPV-positive samples was subsequently performed by GP5+/6+-PCR followed by Luminex suspension array technology. Physical examination and standardized (sexual) history taking was conducted.
Valid neovaginal swabs were obtained from 54 transgender women (median age, 40.7 years [range, 19.2-60.3]; median postoperative time, 2.4 years [range, 1.0-34.2]). No transgender women were employed in the commercial sex industry. Of 28 sexually active transgender women, 6 (20%) tested positive for neovaginal hrHPV including types 16, 45, 51, 59, 66, and X. There were no concomitant neovaginal lesions nor neovaginal symptoms. All sexually inactive transgender women tested negative for neovaginal hrHPV.
A prevalence of neovaginal hrHPV infection of 20% is observed in Dutch transgender women, who self-reported to be sexually active. The clinical consequences neovaginal hrHPV infection in transgender women require further attention.
在全球范围内,跨性别女性是性传播疾病的高负担人群。跨性别女性中已记录到新阴道高危型人乳头瘤病毒(hrHPV)感染,但其患病率仍不清楚。本研究的目的是确定荷兰跨性别女性样本中新阴道hrHPV的患病率。
2015年6月至2015年12月期间,从所有接受阴道成形术并在术后至少1年到我们门诊进行术后随访的跨性别女性中获取新阴道样本。通过HPV风险检测法进行高危型HPV DNA检测和部分基因分型。随后,对非16/18型hrHPV阳性样本进行GP5+/6+-PCR,然后采用Luminex悬浮阵列技术进行基因分型。进行了体格检查和标准化(性)病史采集。
从54名跨性别女性中获得了有效的新阴道拭子(中位年龄40.7岁[范围19.2 - 60.3];中位术后时间2.4年[范围1.0 - 34.2])。没有跨性别女性从事商业性行业。在28名有性行为的跨性别女性中,6名(20%)新阴道hrHPV检测呈阳性,包括16、45、51、59、66和X型。没有同时存在的新阴道病变或新阴道症状。所有无性行为的跨性别女性新阴道hrHPV检测均为阴性。
在自我报告有性行为的荷兰跨性别女性中,观察到新阴道hrHPV感染患病率为20%。跨性别女性新阴道hrHPV感染的临床后果需要进一步关注。